Hepatology Search
Hepatology Hepatology

Conference Reports

The International Liver Congress™ 2019 (ILC 2019)
Vienna, Austria
10 April 2019 - 14 April 2019
12th IDF-WPR Congress & 10th AASD Scientific Meeting
Kuala Lumpur
22 November 2018 - 25 November 2018
2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
San Francisco, California, US
18 January 2018 - 20 January 2018
Asia Pacific Digestive Week 2017 (APDW 2017)
Hong Kong
23 September 2017 - 26 September 2017
26th Conference of the Asian Pacific Association for the Study of the Liver (APASL)
Shanghai, China
15 February 2017 - 19 February 2017
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Oseltamivir cuts recovery time for flu in real world
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Concomitant PAH may up mortality risk in systemic sclerosis
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

Personalizing treatment for chronic angina with concomitant diseases
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Brodalumab sustains long-term safety, efficacy in psoriatic patients
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.